PMC:7306567 / 17076-17321 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":7,"end":13},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"LitCovid-PubTator","denotations":[{"id":"192","span":{"begin":21,"end":33},"obj":"Chemical"},{"id":"195","span":{"begin":229,"end":244},"obj":"Disease"}],"attributes":[{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:D065819"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"MESH:C536203"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T81","span":{"begin":132,"end":134},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T110","span":{"begin":7,"end":13},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T111","span":{"begin":140,"end":141},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T118","span":{"begin":21,"end":33},"obj":"Chemical"},{"id":"T119","span":{"begin":132,"end":134},"obj":"Chemical"}],"attributes":[{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_10023"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_74062"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"LitCovid-sentences","denotations":[{"id":"T114","span":{"begin":0,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T137","span":{"begin":7,"end":13},"obj":"UBERON:0001969"},{"id":"T138","span":{"begin":21,"end":33},"obj":"CHEBI:10023;CHEBI:10023"},{"id":"T6563","span":{"begin":7,"end":13},"obj":"UBERON:0001969"},{"id":"T68072","span":{"begin":21,"end":33},"obj":"CHEBI:10023;CHEBI:10023"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}

{"project":"2_test","denotations":[{"id":"32572532-22610925-47963439","span":{"begin":163,"end":165},"obj":"22610925"},{"id":"32572532-18171251-47963439","span":{"begin":163,"end":165},"obj":"18171251"},{"id":"32572532-21768513-47963439","span":{"begin":163,"end":165},"obj":"21768513"},{"id":"32572532-22751544-47963439","span":{"begin":163,"end":165},"obj":"22751544"},{"id":"T88155","span":{"begin":163,"end":165},"obj":"22610925"},{"id":"T71393","span":{"begin":163,"end":165},"obj":"18171251"},{"id":"T75852","span":{"begin":163,"end":165},"obj":"21768513"},{"id":"T42515","span":{"begin":163,"end":165},"obj":"22751544"}],"text":"Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity."}